Stocks · Healthcare · Biotechnology
Arcturus Therapeutics Holdings Inc. ARCT
$13.03 -1.36% Close, Oct 2, 2026 · NASDAQ · Market cap $370.4M
High risk
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $23.8M, down 79.1% from a year earlier, slowing from -66.4% a quarter earlier.
- Operating margin narrowed to -433.4% from -63.8% a year earlier.
- The stock is in an uptrend: above its 200-day average for 38 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 7%
- Revenue growth, 3-year CAGRBottom 5%
- Revenue growth accelerationBottom 15%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 23%
- Gross marginTop 27%
- Operating marginBottom 18%
- Accruals (lower is better)Top 38%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 27%
- Free-cash-flow yieldBottom 25%
- EBITDA / enterprise valueBottom 16%
- Sales / enterprise valueBottom 35%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 24%
- 6-month returnTop 15%
- 1-year return vs S&P 500Bottom 18%
- Distance from 52-week highBottom 33%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 34%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 22%
- Upside to consensus price targetTop 30%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 8%
- Maximum drawdown, 3 yearsBottom 20%
- Beta vs S&P 500 (lower is better)Bottom 8%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -66.4% | -79.1% | ↓ |
| Gross margin | 100.0% | 83.2% | ↓ |
| Operating margin | -63.8% | -433.4% | ↓ |
| FCF margin | -57.3% | -306.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -79.1% | -66.4% | ↓ | Bottom 7% |
| Gross margin | 83.2% | 100.0% | ↓ | Top 27% |
| Operating margin | -433.4% | -63.8% | ↓ | Bottom 18% |
| Net margin | -391.9% | -52.9% | ↓ | — |
| Free-cash-flow margin | -306.9% | -57.3% | ↓ | — |
| Return on invested capital | -53.0% | — | Bottom 23% | |
| Revenue growth, 3-year CAGR | -31.1% | — | Bottom 5% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -9.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 88.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -10.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -3.36%
- Shareholder yield
- -3.36%
- Share count change, 1 year
- +4.8%
- Share count change, 3-year CAGR
- +2.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +12.5%
- Average 2-day reaction, last 8
- -0.9%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $30.50
- Target vs current price
- +134.1%
- Analysts with a rating
- 21
- Share rating Buy or Strong Buy
- 57%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +15.7% | -2.9% | +21.4% | +167.4% | — |
| May 7, 2026 | +7.4% | -2.5% | -9.5% | -11.9% | -34.3% |
| Mar 3, 2026 | -12.0% | -5.3% | -11.9% | -17.4% | -8.3% |
| Nov 10, 2025 | +38.7% | +0.7% | -16.6% | -14.6% | -19.5% |
| Aug 11, 2025 | +61.9% | -4.4% | +63.6% | +49.8% | -21.9% |
| May 12, 2025 | +67.1% | +5.6% | +6.1% | +14.2% | +11.2% |
| Mar 6, 2025 | -236.4% | -0.5% | -11.2% | -36.4% | -21.9% |
| Nov 7, 2024 | +62.9% | +2.2% | +4.6% | -2.6% | -2.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.84 | -$1.00 | +15.7% | $3.0M |
| May 7, 2026 | -$0.95 | -$1.03 | +7.4% | $2.1M |
| Mar 3, 2026 | -$1.03 | -$0.92 | -12.0% | $7.2M |
| Nov 10, 2025 | -$0.49 | -$0.80 | +38.7% | $17.2M |
| Aug 11, 2025 | -$0.34 | -$0.89 | +61.9% | $28.3M |
| May 12, 2025 | -$0.52 | -$1.58 | +67.1% | $29.4M |
| Mar 6, 2025 | -$1.11 | -$0.33 | -236.4% | $22.8M |
| Nov 7, 2024 | -$0.26 | -$0.70 | +62.9% | $38.8M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 8.48× | — | — | Bottom 35% |
| Free-cash-flow yield | -19.72% | — | — | Bottom 25% |
| Earnings yield | -25.56% | — | — | Bottom 27% |
P/E over the past five years
Range 7.1× – 84.0× since Dec 31, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 40
- Days above the 200-day average
- 38
- 50-day average slope (20 days)
- +37.2%
- 200-day average slope (20 days)
- +10.2%
- Distance from 50-day average
- +10.6%
- Distance from 200-day average
- +53.3%
- RSI (14)
- 45.5
- Relative volume
- 0.93×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 99.6%
- Volatility vs own 5-year history
- 75th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.29
- Correlation with S&P 500
- 0.35
- Current drawdown from 1-year high
- -43.7%
- Maximum drawdown, 3 years
- -87.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 7, 2020 | Jul 24, 2026 | -95.5% | 1412 days | Not yet recovered |
| Nov 6, 2020 | Nov 9, 2020 | -45.4% | 1 days | 13 days (Nov 27, 2020) |
| Oct 16, 2020 | Oct 21, 2020 | -14.6% | 3 days | 8 days (Nov 2, 2020) |
| Nov 30, 2020 | Dec 1, 2020 | -11.2% | 1 days | 2 days (Dec 3, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $370.4M
- EPS, diluted (TTM)
- -$3.33
- Revenue (TTM)
- $23.8M
- 52-week range
- $5.50 – $24.17
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $12.4M | $205.8M | $157.7M | $138.4M | $67.2M |
| Gross profit | $12.4M | $205.8M | $157.7M | $138.4M | $64.2M |
| Operating income | -$202.9M | $12.2M | -$78.2M | -$95.7M | -$75.0M |
| Net income | -$203.7M | $9.3M | -$29.7M | -$80.9M | -$65.8M |
| EPS (diluted) | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.8M | $21.0M | $29.4M | $24.5M | $17.2M | $3.1M | $610,000 | $3.0M |
| Net income | -$6.9M | -$30.0M | -$14.1M | -$9.2M | -$13.4M | -$29.1M | -$27.0M | -$23.8M |
| EPS (diluted) | -$0.26 | -$1.11 | -$0.52 | -$0.34 | -$0.49 | -$1.05 | -$0.95 | -$0.84 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$135.0M | $32.0M | -$18.1M | -$59.7M | -$74.3M |
| Capital expenditure | -$3.4M | -$7.7M | -$2.9M | -$648,000 | -$230,000 |
| Free cash flow | -$138.4M | $24.3M | -$21.0M | -$60.4M | -$74.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $515,000 | $411,000 | $609,000 | $682,000 | $13.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $191.5M
- Total assets
- $224.3M
- Total liabilities
- $52.5M
- Total debt
- $22.9M
- Net debt
- -$168.6M
- Shareholders’ equity
- $171.8M
As of Jun 30, 2026 (filed Aug 6, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jan 8, 2013 | $0.01 | Jan 15, 2013 |
| Jan 4, 2013 | $0.01 | Jan 15, 2013 |
| Dec 5, 2012 | $0.01 | Dec 15, 2012 |
| Nov 6, 2012 | $0.01 | Nov 15, 2012 |
| Oct 3, 2012 | $0.01 | Oct 15, 2012 |
| Sep 5, 2012 | $0.01 | Sep 15, 2012 |
| Aug 6, 2012 | $0.01 | Aug 15, 2012 |
| Jul 3, 2012 | $0.01 | Jul 15, 2012 |
Short interest
- Shares sold short
- 5,467,974
- Days to cover
- 6.37
- Change vs previous report
- -10.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Nov 16, 2017
- 1-for-7